Cipla-SIGA Antibacterial Alliance To Tackle Resistance, Biothreats
BARDA Among Customers?
Executive Summary
Cipla, which has long-standing experience in antibiotic development in India, strikes alliance with US firm SIGA Technologies. The partners are targeting novel antibacterials, especially against biothreats, and expect to cater to US agency BARDA, among others.
You may also be interested in...
EU Crunch Time Nears For Amgen’s Novel Lung Cancer Drug Sotorasib
The European Medicines Agency is expected to make recommendations on EU marketing authorization for 10 new medicines at its monthly meeting this week. They include products for non-small cell lung cancer, COVID-19, kidney disease, smallpox and migraine.
Cipla CEO On Lung Leadership Beyond Asthma, AMR Plans
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.
How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.